| 2026-03-18 |
详情>>
内部人交易：
Caljouw Lynne J股份减少2480.00股
|
| 2026-02-27 |
详情>>
股本变动：
变动后总股本14579.95万股
|
| 2026-02-27 |
详情>>
业绩披露：
2025年年报每股收益0.21美元,归母净利润3130.00万美元,同比去年增长-75.64%
|
| 2026-02-19 |
财报披露：
美东时间 2026-02-19 盘后发布财报
|
| 2025-11-03 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.22美元,归母净利润-3193.6万美元,同比去年增长-126.03%
|
| 2025-07-29 |
详情>>
业绩披露：
2025年中报每股收益0.89美元,归母净利润1.31亿美元,同比去年增长-11.6%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益0.47美元,归母净利润6991.90万美元,同比去年增长-8.03%
|
| 2025-04-29 |
股东大会：
将于2025-06-10召开股东大会
会议内容 ▼▲
- 1.Election of Directors
2.Non-Binding, Advisory Vote on Executive Compensation
3.Ratification of Independent Registered Public Accounting Firm
4.Non-Binding, Advisory Vote on Directors' Compensation Report
5.Approval of Directors' Compensation Policy
6.Appointment of UK Statutory Auditor
7.Authorization of the Audit Committee to Determine U.K. Statutory Auditor Compensation
8.Approval of Receipt of 2024 Annual Report and Accounts
9.Approval of Forms of Share Repurchase Contracts and Share Repurchase Counterparties
10.Authorization of the Board to Issue Equity Securities
11.Authorization of the Board to Issue Equity Securities without Rights of Pre-emption
12.Authorization of the Board to Issue Equity Securities Under Equity Incentive Plans
13.Authorization of the Board to Issue Equity Securities Under Equity Incentive Plans without Rights of Pre-emption
|
| 2025-02-28 |
详情>>
业绩披露：
2024年年报每股收益0.85美元,归母净利润1.28亿美元,同比去年增长3386.70%
|
| 2025-02-28 |
详情>>
业绩披露：
2022年年报每股收益2.00美元,归母净利润3.11亿美元,同比去年增长-14.55%
|
| 2024-11-04 |
详情>>
业绩披露：
2024年三季报(累计)每股收益0.81美元,归母净利润1.23亿美元,同比去年增长-38.14%
|
| 2024-11-04 |
详情>>
业绩披露：
2023年三季报(累计)每股收益1.30美元,归母净利润1.98亿美元,同比去年增长0.40%
|
| 2024-07-29 |
详情>>
业绩披露：
2024年中报每股收益0.98美元,归母净利润1.48亿美元,同比去年增长9.00%
|
| 2024-04-29 |
股东大会：
将于2024-06-11召开股东大会
会议内容 ▼▲
- 1.Election of Directors
2.Non-Binding, Advisory Vote on Executive Compensation
3.Ratification of Independent Registered Public Accounting Firm
4.Non-Binding, Advisory Vote on Directors' Compensation Report
5.Appointment of UK Statutory Auditor
6.Authorization of the Audit Committee to Determine U.K. Statutory Auditor Compensation
7.Approval of Receipt of 2023 Annual Report and Accounts
8.Approval of Forms of Share Repurchase Contracts and Share Repurchase Counterparties
9.Authorization of the Board to Issue Equity Securities
10.Authorization of the Board to Issue Equity Securities without Rights of Pre-emption
11.Authorization of the Board to Issue Equity Securities Under Equity Incentive Plans
12.Authorization of the Board to Issue Equity Securities Under Equity Incentive Plans without Rights of Pre-emption
|
| 2024-04-29 |
详情>>
业绩披露：
2024年一季报每股收益0.51美元,归母净利润7602.10万美元,同比去年增长-12.03%
|
| 2024-02-29 |
详情>>
业绩披露：
2023年年报每股收益-0.03美元,归母净利润-390.9万美元,同比去年增长-101.26%
|
| 2023-04-13 |
股东大会：
将于2023-05-25召开股东大会
会议内容 ▼▲
- 1.Election of Directors
2.Non-Binding, Advisory Vote on Executive Compensation
3.Ratification of Independent Registered Public Accounting Firm
4.Non-Binding, Advisory Vote on Directors' Compensation Report
5.Appointment of UK Statutory Auditor
6.Authorization of the Audit Committee to Determine U.K. Statutory Auditor Compensation
7.Approval of Receipt of 2022 Annual Report and Accounts
8.Approval of Forms of Share Repurchase Contracts and Share Repurchase Counterparties
9.Authorization of the Board to Issue Equity Securities
10.Authorization of the Board to Issue Equity Securities without Rights of Pre-emption
11.Authorization of the Board to Issue Equity Securities Under Equity Incentive Plans
12.Authorization of the Board to Issue Equity Securities Under Equity Incentive Plans without Rights of Pre-emption
|
| 2022-04-14 |
股东大会：
将于2022-05-26召开股东大会
会议内容 ▼▲
- 1.Election of Directors
2.Non-Binding, Advisory Vote on Executive Compensation
3.Ratification of Independent Registered Public Accounting Firm
4.Non-Binding, Advisory Vote on Directors' Compensation Report
5.Approval of Directors' Compensation Policy
6.Reappointment of UK Statutory Auditor
7.Authorization of the Audit Committee to Determine U.K. Statutory Auditor Compensation
8.Approval of Receipt of 2021 Annual Report and Accounts
9.Approval of Forms of Share Repurchase Contracts and Share Repurchase Counterparties
10.Authorization of the Board to Issue Equity Securities
11.Authorization of the Board to Issue Equity Securities without Rights of Pre-emption
12.Authorization of the Board to Issue Equity Securities Under Equity Incentive Plans
13.Authorization of the Board to Issue Equity Securities Under Equity Incentive Plans without Rights of Pre-emption
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-15 |
股东大会：
将于2021-05-27召开股东大会
会议内容 ▼▲
- 1.Election of eleven directors.
2.Advisory resolution to approve the compensation of our named executive officers ("NEOs").
3.Approval of the Company's 2021 Equity Incentive Plan.
4.Advisory ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal year 2021.
5.Advisory resolution to approve our Director Compensation Report.
6.Approval of the appointment of Ernst & Young LLP as our U.K. statutory auditor for fiscal year 2021.
7.Authorization of the Audit Committee, for and on behalf of the Board, to determine the remuneration of Ernst & Young LLP, in its capacity as our U.K. statutory auditor.
8.Receipt of our 2020 Annual Report and Accounts.
9.Authorization of the Board, in accordance with section 551 of the U.K. Companies Act 2006, as amended (the "U.K. Companies Act"), to exercise all powers of the Company to issue equity securities.
10.Authorization of the Board, in accordance with section 570 of the U.K. Companies Act, to issue equity securities without the rights of preemption provided by section 561 of the U.K. Companies Act.
11.Authorization of the Board, in accordance with section 551 of the U.K. Companies Act, to exercise all powers of the Company to issue equity shares under our equity incentive plans.
12.Authorization of the Board, in accordance with section 570 of the U.K. Companies Act, to issue equity shares under our equity incentive plans without the rights of preemption provided by section 561 of the U.K. Companies Act.
|
| 2020-04-22 |
股东大会：
将于2020-05-28召开股东大会
会议内容 ▼▲
- 1.Election of eleven directors.
2.Advisory resolution to approve the compensation of our named executive officers ("NEOs").
3.Advisory vote to approve the frequency of future "say-on-pay" votes.
4.Advisory ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal year 2020.
5.Advisory vote on our Director Compensation Report.
6.Approval of the appointment of Ernst & Young LLP as our U.K. statutory auditor for fiscal year 2020.
7.Authorization of the Audit Committee, for and on behalf of the Board, to determine the remuneration of Ernst & Young LLP, in its capacity as our U.K. statutory auditor.
8.Receipt of our 2019 Annual Report and Accounts.
9.Approval of the form of three share repurchase contracts and the potential repurchase counterparties.
10.Authorization of the Board, in accordance with section 551 of the U.K. Companies Act 2006, as amended (the "U.K. Companies Act"), to exercise all powers of the Company to issue equity securities.
11.Authorization of the Board, in accordance with section 570 of the U.K. Companies Act, to issue equity securities without the rights of preemption provided by section 561 of the U.K. Companies Act.
12.Authorization of the Board, in accordance with section 551 of the U.K. Companies Act, to exercise all powers of the Company to issue equity shares under our equity incentive plans.
13.Authorization of the Board, in accordance with section 570 of the U.K. Companies Act, to issue equity shares under our equity incentive plans without the rights of preemption provided by section 561 of the U.K. Companies Act.
|
| 2019-04-30 |
股东大会：
将于2019-05-28召开股东大会
会议内容 ▼▲
- 1.Election of nine directors.
2.Advisory resolution to approve the compensation of our named executive officers ("NEOs").
3.Advisory ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2019.
4.Advisory vote on our Director Compensation Report.
5.Approval of our Director Compensation Policy.
6.Approval of the appointment of Ernst & Young LLP as our U.K. statutory auditor.
7.Authorization of the Audit Committee, for and on behalf of the Board, to determine the remuneration of Ernst & Young LLP, in its capacity as our U.K. statutory auditor.
8.Receipt of our 2018 Annual Report and Accounts.
9.Approval of the form of two share repurchase contracts and the potential repurchase counterparties.
10.Authorization of the Board, in accordance with section 551 of the U.K. Companies Act 2006, as amended (the "U.K. Companies Act"), to exercise all powers of the Company to issue equity securities.
11.Authorization of the Board, in accordance with section 570 of the U.K. Companies Act, to issue equity securities without the rights of preemption provided by section 561 of the U.K. Companies Act.
12.Authorization of the Board, in accordance with section 551 of the U.K. Companies Act, to exercise all powers of the Company to issue equity shares under our equity incentive plans.
13.Authorization of the Board, in accordance with section 570 of the U.K. Companies Act, to issue equity shares under our equity incentive plans without the rights of preemption provided by section 561 of the U.K. Companies Act.
|
| 2018-04-27 |
股东大会：
将于2018-05-31召开股东大会
会议内容 ▼▲
- 1.Election of nine directors.
2.Advisory resolution to approve the compensation of our named executive officers ("NEOs").
3.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm.
4.Re-appointment of Ernst & Young LLP as our U.K. statutory auditor.
5.Authorization of the Audit Committee, for and on behalf of the Board, to determine the remuneration of Ernst & Young LLP, in its capacity as our U.K. statutory auditor.
6.Receipt of the audited annual report for Sensata Technologies Holding N.V. ("Sensata NV") for the year ended December 31, 2017.
7.Approval of the form of two share repurchase contracts and the potential repurchase counterparties.
8.Authorization of the Board, in accordance with section 551 of the Companies Act 2006 (the "Companies Act"), to exercise all powers of the Company to allot shares in the Company under our equity incentive plans.
9.Authorization of the Board, in accordance with section 570 of the Companies Act, to allot shares in the Company under our equity incentive plans without the rights of preemption provided by section 561 of the Companies Act.
|
| 2018-01-19 |
股东大会：
将于2018-02-16召开股东大会
会议内容 ▼▲
- 1.To approve the amendment of the articles of association of Sensata-Netherlands (the “Sensata-Netherlands Articles”) in connection with the proposed Merger, as defined herein, and authorize any and all lawyers and (deputy) civil law notaries practicing at Loyens & Loeff N.V., Amsterdam, the Netherlands, to execute the notarial deed of amendment of the articles of association to affect the aforementioned amendment of the Sensata-Netherlands Articles.
2.To approve the cross-border merger between Sensata-Netherlands and Sensata Technologies Holding plc (“Sensata-UK”), a newly-formed public limited company incorporated under the laws of England and Wales, with Sensata-Netherlands being the disappearing entity and Sensata-UK being the surviving entity (the “Merger”), pursuant to the common draft terms of the cross-border legal merger (the “Merger Proposal”), a copy of which is attached to this proxy statement/prospectus as Annex A.
3.To transact such other business as may properly come before the Extraordinary Meeting or any adjournments thereof.
|
| 2017-04-20 |
股东大会：
将于2017-05-18召开股东大会
会议内容 ▼▲
- 1.To elect the ten director nominees named in the Proxy Statement to hold office until the 2018 Annual General Meeting of Shareholders;
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for fiscal year 2017;
3a.To discuss implementation of the remuneration policy in 2016;b.To adopt our Dutch statutory annual accounts for fiscal year 2016, to discuss the annual report of our directors for fiscal year 2016, to authorize the preparation of our Dutch statutory annual accounts and the annual report of our directors for fiscal year 2016 in the English language, and to discuss our reservation and dividend policy;
4.To discharge members of the Board of Directors from certain liabilities for fiscal year 2016;
5.To extend to the Board of Directors for a period of 18 months from the date of the General Meeting the authority to repurchase up to 10% of the outstanding ordinary shares, as determined on the record date, in the capital of the Company, on the open market, through privately negotiated transactions or in one or more self tender offers, at prices per share not less than the nominal value of a share and not higher than 110% of the market price at the time of the transaction;
6.To approve executive compensation on an advisory basis;
7.To amend the Company's Articles of Association to change its registered office to Hengelo, The Netherlands and to authorize each member of the Board of Directors and each employee of Loyens & Loeff N.V. to execute the deed of amendment;
8.To transact such other business as may properly come before the General Meeting or any adjournments thereof.
The Board of Directors recommends a FOR vote for each of the director nominees with respect to proposal (1), and a FOR vote for each of proposals (2), (3b), (4), (5), (6), and (7) above.
|
| 2016-04-21 |
股东大会：
将于2016-05-19召开股东大会
会议内容 ▼▲
- 1.To elect ten (10) directors to serve until the 2017 Annual General Meeting of Shareholders, or until their respective successors are elected and qualified or until his or her earlier death, resignation, or removal;
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
3a.To discuss implementation of the remuneration policy in 2015;
3b.To adopt our Dutch statutory annual accounts for the fiscal year ended December 31, 2015, to discuss the annual report of our directors for fiscal year 2015, to authorize the preparation of our 2015 Dutch statutory annual accounts and the annual report of our directors for fiscal year 2015 in the English language, and to discuss our reservation and dividend policy;
4.To discharge members of the Board of Directors from certain liabilities for fiscal year 2015;
5.To extend to the Board of Directors for a period of 18 months from the date of the General Meeting the authority to repurchase up to 10% of the outstanding ordinary shares, as determined on the record date, in the capital of the Company, on the open market, through privately negotiated transactions or in one or more self tender offers, at prices per share not less than the nominal value of a share and not higher than 110% of the market price at the time of the transaction;
6.To amend the Company's Articles of Association to include a derivative disclosure requirement and to authorize each member of the Board of Directors and each employee of Loyens & Loeff N.V. to execute the deed of amendment;
7.To consider and approve an advisory proposal on the 2015 compensation of the Named Executive Officers as disclosed herein under “Executive Compensation;"
8.To amend the director remuneration policy and to implement a director stock ownership requirement;
9.To transact such other business as may properly come before the General Meeting or any adjournments thereof.
|